Results 11 to 20 of about 18,546 (173)

Anakinra treatment in multisystemic inflammatory syndrome in children (MIS-C) associated with COVID-19

Frontiers in Pediatrics, 2022
ObjectiveThe study aimed to report the efficacy and safety of anakinra treatment in patients with the refractory multisystemic inflammatory syndrome in children (MIS-C).MethodsThis is a cross-sectional retrospective study consisting of pediatric patients
Betul SÖZERİ, Çaǧlayan Sengül, ÖZTÜRK Kubra   +2 more
exaly   +3 more sources

Safety of intravenous use of anakinra in pediatric inflammatory conditions: a retrospective multicenter study [PDF]

Pediatric Rheumatology Online Journal
Purpose Anakinra is a recombinant human interleukin-1 receptor antagonist primarily administered by subcutaneous injection for the treatment of autoinflammatory conditions. Intravenous use of anakinra is only sparsely described in the literature. The aim
Marta Klanjscek, Matteo Trevisan, Serena Pastore, Manuela Pardeo, Alberto Tommasini, Roberta Caorsi, Gianluca Dell’Orso, Sarah Abu Rumeileh, Chiara Conti, Carmelita D’Ippolito, Manuela Cortesi, Natasha Maximova, Marco Cattalini, Gabriele Simonini, Marco Gattorno, Fabrizio De Benedetti, Andrea Taddio, Claudia Bracaglia   +17 more
doaj   +2 more sources

Efficacy and safety of anakinra in adults presenting deteriorating respiratory symptoms from COVID-19: A randomized controlled trial.

PLoS ONE, 2022
ObjectiveWe aimed to investigate whether anakinra, an interleukin-1receptor inhibitor, could improve outcome in moderate COVID-19 patients.MethodsIn this controlled, open-label trial, we enrolled adults with COVID-19 requiring oxygen.
Alexandra Audemard-Verger, Amélie Le Gouge, Vincent Pestre, Johan Courjon, Vincent Langlois, Marc-Olivier Vareil, Mathilde Devaux, Boris Bienvenu, Vincent Leroy, Radjiv Goulabchand, Léa Colombain, Adrien Bigot, Thomas Guimard, Youcef Douadi, Geoffrey Urbanski, Jean François Faucher, Laurence Maulin, Bertrand Lioger, Jean-Philippe Talarmin, Matthieu Groh, Joseph Emmerich, Sophie Deriaz, Nicole Ferreira-Maldent, Ann-Rose Cook, Céline Lengellé, Hélène Bourgoin, Arsène Mekinian, Achille Aouba, François Maillot, Agnès Caille   +29 more
doaj   +2 more sources

Clinical outcomes and safety of anakinra in the treatment of multisystem inflammatory syndrome in children: a single center observational study

Pediatric Rheumatology Online Journal, 2023
Background and objective Evidence for the treatment of multisystem inflammatory syndrome in children (MIS-C) is lacking. Anakinra, which targets IL-1-mediated inflammation, is reserved for refractory cases of MIS-C; however, its use in the treatment of ...
Brian L.P. Dizon, Christopher Redmond, Emily C. Gotschlich, Sangeeta Sule, Tova Ronis, Kathleen M. Vazzana, Matthew A. Sherman, Rachael Connor, Abigail Bosk, Niti Dham, Ashraf S. Harahsheh, Elizabeth Wells, Roberta DeBiasi, Hemalatha Srinivasalu   +13 more
doaj   +1 more source

Intravenous administration of anakinra in children with macrophage activation syndrome

Pediatric Rheumatology Online Journal, 2021
Background Subcutaneous anakinra is an interleukin-1 inhibitor used to treat juvenile idiopathic arthritis. Recent reports suggest anakinra can be a valuable addition to the treatment of COVID-19 associated cytokine storm syndrome and the related ...
Omkar Phadke, Kelly Rouster-Stevens, Helen Giannopoulos, Shanmuganathan Chandrakasan, Sampath Prahalad   +4 more
doaj   +1 more source

Anakinra in hospitalized patients with severe COVID-19 pneumonia requiring oxygen therapy: Results of a prospective, open-label, interventional study

International Journal of Infectious Diseases, 2021
Objective: The aim of this study was to evaluate the efficacy of anakinra in patients who were admitted to hospital for severe COVID-19 pneumonia requiring oxygen therapy.
A. Balkhair, I. Al-Zakwani, M. Al Busaidi, A. Al-Khirbash, S. Al Mubaihsi, H. BaTaher, J. Al Aghbari, I. Al Busaidi, M. Al Kindi, S. Baawain, A. Al Alawi, A. Al Lawati, B. Al Rawahi, K. Al-Baimani, K. Al Zidi, N. Elfatih, B. Dawud, B. John, F. Rehman, F. Yousif, G. Al Khadouri, I. Saber, J. Lal, M. Gargouri, M. Al-Ward, N. AbuDraz, S. Al Ruqeishi, S. Kumar, W. Abdelmottaleb, Z. Al-Naamani, Z. Bin Nazar, O. Balkhair   +31 more
doaj   +1 more source

Impact of anakinra use on clinical outcomes in children with moderate or severe multisystem inflammatory syndrome in children: a propensity score matched retrospective cohort study

Pediatric Rheumatology Online Journal, 2023
Background The treatment of children with multisystem inflammatory syndrome in children (MIS-C) related to SARS-CoV-2 infection involves immunomodulatory therapies such as IVIG and steroids.
Esra B. Akkoyun, Zachary Most, Harita Katragadda, Andrew Yu, Lorien Nassi, Nicole Oakman, Sarah Ginsburg, Mia Maamari   +7 more
doaj   +1 more source

Interleukin‐1 Blockade Inhibits the Acute Inflammatory Response in Patients With ST‐Segment–Elevation Myocardial Infarction

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2020
Background ST‐segment–elevation myocardial infarction is associated with an intense acute inflammatory response and risk of heart failure. We tested whether interleukin‐1 blockade with anakinra significantly reduced the area under the curve for hsCRP ...
Antonio Abbate, Cory R. Trankle, Leo F. Buckley, Michael J. Lipinski, Darryn Appleton, Dinesh Kadariya, Justin M. Canada, Salvatore Carbone, Charlotte S. Roberts, Nayef Abouzaki, Ryan Melchior, Sanah Christopher, Jeremy Turlington, George Mueller, James Garnett, Christopher Thomas, Roshanak Markley, George F. Wohlford, Laura Puckett, Horacio Medina de Chazal, Juan G. Chiabrando, Edoardo Bressi, Marco Giuseppe Del Buono, Aaron Schatz, Chau Vo, Dave L. Dixon, Giuseppe G. Biondi‐Zoccai, Michael C. Kontos, Benjamin W. Van Tassell   +28 more
doaj   +1 more source

The Effect of Anakinra on Acrylamide-induced Peripheral Neuropathy and Neuropathic Pain in Rats

Brazilian Journal of Pharmaceutical Sciences, 2023
Acrylamide is a neurotoxic compound. Moreover, anakinra is an interleukin-1 (IL-1) receptor antagonist used in rheumatoid arthritis treatment. This study investigated the effect of anakinra on acrylamide-related neuropathy and neuropathic pain ...
Alevtina Ersoy, Ceyda Tanoglu, Gulce Naz Yazici, Taha Abdulkadir Coban, Renad Mammadov, Halis Suleyman   +5 more
doaj   +1 more source

Anakinra treatment for refractory cerebral autoinflammatory responses

Annals of Clinical and Translational Neurology, 2022
Refractory cerebral autoinflammatory–autoimmune diseases are often associated with dysregulated innate immunity and are targeted by anakinra, an interleukin‐1 receptor antagonist.
Yoonhyuk Jang, Woo‐Jin Lee, Han Sang Lee, Kon Chu, Sang Kun Lee, Soon‐Tae Lee   +5 more
doaj   +1 more source